Publication details

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.

Authors

RÁČIL Zdeněk RÁZGA Filip DRÁPALOVÁ Jana BUREŠOVÁ Lucie ŽÁČKOVÁ Daniela PALACKOVÁ Martina SEMERÁD Lukáš MALÁSKOVÁ Ludmila HALUZÍK Martin MAYER Jiří

Year of publication 2013
Type Article in Periodical
Magazine / Source Haematologica
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.haematologica.org/content/early/2013/05/03/haematol.2013.086355.abstract?cited-by=yes&legid=haematol;haematol.2013.086355v1
Doi http://dx.doi.org/10.3324/haematol.2013.086355
Field Oncology and hematology
Keywords Nilotinib; insulin resistance
Attached files
Description For the first time we have clarified the mechanism of impaired glucose metabolism in CML patients treated with nilotinib, which occurs via rapidly developed tissue insulin resistance and compensatory hyperinsulinemia. It also at least partially explains the fast development of dyslipidemia and probably also PAO in these CML patients. However, further studies that include a larger patient cohort, as well as in vitro tests to confirm postreceptor insulin resistance, are needed, and these are already ongoing in our study group.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info